Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CMS “Functional Equivalence” Standard Targeted In Medicare Bills

Executive Summary

CMS would be prohibited from using the Aranesp/ Procrit "functional equivalence" decision as a precedent in future reimbursement rulings under both the House and Senate versions of the Medicare prescription drug bill
Advertisement

Related Content

BIO Creates Policy Chief Position, Plans Reports Justifying Biotech Prices
BIO Creates Policy Chief Position, Plans Reports Justifying Biotech Prices
CMS Keeps “Functional Equivalence” In 2004; Amgen Submits Aranesp Data
“Functional Equivalence” Battle Has Just Begun, Sen. Hatch Aide Says
AWP Reform: House Bill Offers Choice Of “Average Sales Price” Or Bids
Senate Medicare Vote Suggests $400 Bil. Rx Benefit Is Winning Formula
Senate AWP Plan Directs HHS To Determine “Market Price” For Chemotherapy
CMS Defends “Functional Equivalence”; AWP Proposal Ready, Scully Says
Aranesp, Procrit Are “Functionally Equivalent,” CMS Says In Final OPPS Rule
Aranesp, Procrit Are “Functionally Equivalent,” CMS Says In Final OPPS Rule
Advertisement
UsernamePublicRestriction

Register

PS042000

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel